Market Place
Sourcing Support
All News #Library
Biotech
Nkarta Secures FDA Approval For Outpatient NKX019 Dosing
15 Apr 2026 //
FIRSTWORD PHARMA
Nkarta To Participate In Needham Virtual Healthcare Conference
09 Apr 2026 //
GLOBENEWSWIRE
Nkarta Unveils 2025 Financials And Corporate Achievements
25 Mar 2026 //
GLOBENEWSWIRE
Nkarta Unveils Q3 2025 Financials & Corporate Achievements
10 Nov 2025 //
GLOBENEWSWIRE
Nkarta To Present Poster At (ACR) Convergence Meeting
22 Oct 2025 //
GLOBENEWSWIRE
Nkarta CEO Urges US Government To Abandon China Policies
16 Oct 2025 //
FIERCE BIOTECH
Nkarta Joins H.C. Wainwright `HCW@Home` Series
23 Jul 2025 //
GLOBENEWSWIRE
Nkarta to Participate in March Investor Conferences
25 Feb 2025 //
GLOBENEWSWIRE
Nkarta Announces IND Clearance for Myasthenia Gravis Trial
05 Dec 2024 //
GLOBENEWSWIRE
Nkarta continues pivot to lupus by shelving lymphoma program
11 Nov 2024 //
FIERCE BIOTECH
Nkarta Initiates Clinical Trial of NKX019 in Lupus Nephritis
27 Jun 2024 //
GLOBENEWSWIRE
Nkarta Announces Pricing of $240 Million Underwritten Offering
25 Mar 2024 //
GLOBENEWSWIRE
Nkarta to Participate at Upcoming Investor Conferences
07 Nov 2023 //
GLOBENEWSWIRE
Nkarta moves cell therapy into autoimmune trials, lays off staff
18 Oct 2023 //
FIERCE BIOTECH
Nkarta trims headcount as it sets sights on autoimmune cell therapy
17 Oct 2023 //
ENDPTS
Nkarta to Participate at Upcoming Investor Conference
03 Aug 2023 //
GLOBENEWSWIRE
Nkarta Appoints Alyssa Levin Chief Financial and Business Officer
05 Jul 2023 //
GLOBENEWSWIRE
Nkarta`s cell therapy needs specific pre-conditioning
27 Jun 2023 //
FIERCE BIOTECH
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101
26 Jun 2023 //
GLOBENEWSWIRE
Nkarta Presents NKX019 Data at European Hematology Association 2023
10 Jun 2023 //
GLOBENEWSWIRE
Nkarta to Present NKX019 Phase 1 Dose Escalation Data at 2023 Congress
11 May 2023 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.